Focused on Preventing Aggressive Cancer from Spreading

MetaStat is a precision medicine company dedicated to improving survival of patients with aggressive cancer. Our goal is to transform aggressive cancer into a manageable disease. We do this through targeted therapies that arrest metastatic progression and improve survival.

Our therapeutic approach targets the MENA pathway, a critical metastatic pathway responsible for driving tumor resistance and the spread of aggressive cancer.  Until recently, the MENA pathway had been considered “undrugable”. We are developing novel inhibitors targeting MAPKAPK2 based on the breakthrough discovery of its role in activation of the MENA pathway.  MetaStat is leveraging a proven and highly successful approach in oncology through the development of small molecule kinase inhibitors. We believe our inhibitors can reverse tumor cell resistance to traditional therapies and block the spread of aggressive cancer. 

MetaStat’s head office, research laboratories, and state-of-the-art CLIA-certified laboratory is located in the Innovation and Design Building in Boston’s Seaport District.

Recent Scientific & Clinical Publications & Presentations